Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13640415 | 0.75 | APLNR (0.33) | APLNR | |
| SCHEMBL15085805 | 0.71 | — | — | |
| SCHEMBL25554207 | 0.70 | FFAR3 (0.46) | EPHX2APLNR | |
| SCHEMBL26084002 | 0.69 | — | — | |
| SCHEMBL4327201 | 0.67 | EPHX2 (0.33) | EPHX2APLNR | |
| SCHEMBL8277249 | 0.67 | TSHR (0.42) | — | |
| SCHEMBL8277960 | 0.66 | CYP2C19 (0.41) | — | |
| SCHEMBL31268179 | 0.66 | EPHX2 (0.32) | EPHX2APLNR | |
| Acetic Acid SCHEMBL987785 | 0.65 | GAA (0.49) | — | |
| Acetic Acid SCHEMBL987542 | 0.64 | GAA (0.41) | APLNR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD | 2015-01-22 | — | — | US | disclosed |
| US-8859505-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8859605-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-10-14 | — | — | US | disclosed |
| US-8815809-B2 | Cysteine protease inhibitors | MEDIVIR UK LTD (GB) | 2014-08-26 | — | — | US | disclosed |
| US-20130172232-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2013-07-04 | — | — | US | disclosed |
| US-20120309673-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2012-12-06 | — | — | US | disclosed |
| US-20120283305-A1 | CYSTEINE PROTEASE INHIBITORS | MEDIVIR UK LTD (GB) | 2012-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150025250-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | EPHX2 258/4885APLNR 3507/4885 |
| US-20120309673-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | EPHX2 240/4885APLNR 3877/4885 |
| US-20120283305-A1 | CYSTEINE PROTEASE INHIBITORS | CTSS, CTSB, CTRB1 | EPHX2 496/4885APLNR 3589/4885 |
| US-20130172232-A1 | CYSTEINE PROTEASE INHIBITORS | CTSB, CTSS, CTRB1 | EPHX2 258/4885APLNR 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.